The trials, involving 500 volunteers, will end on December 31, 2023, the registry added.
This form of the vaccine is more suitable for rolling out to large populations and has fewer side effects.
The Gamaleya Research Centre is the developer of the world's first COVID-19 vaccine, Sputnik V. The shot has been authorised for use in 70 countries, with a total population of about 4 billion people. In terms of the number of approvals from government regulators, it ranks second in the world.